Targeting HIF‑2α and VEGF in Post-Immunotherapy RCC: Belzutifan + Lenvatinib Clinical Insights
The combination of belzutifan (WELIREG) plus lenvatinib (LENVIMA) met the primary endpoint of progression-free survival in the Phase 3 LITESPARK-011 trial in patients with previously...
